160 related articles for article (PubMed ID: 17125248)
1. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
Trotter BW; Nanda KK; Kett NR; Regan CP; Lynch JJ; Stump GL; Kiss L; Wang J; Spencer RH; Kane SA; White RB; Zhang R; Anderson KD; Liverton NJ; McIntyre CJ; Beshore DC; Hartman GD; Dinsmore CJ
J Med Chem; 2006 Nov; 49(24):6954-7. PubMed ID: 17125248
[TBL] [Abstract][Full Text] [Related]
2. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.
Blass BE; Fensome A; Trybulski E; Magolda R; Gardell SJ; Liu K; Samuel M; Feingold I; Huselton C; Jackson CM; Djandjighian L; Ho D; Hennan J; Janusz JM
J Med Chem; 2009 Nov; 52(21):6531-4. PubMed ID: 19888755
[TBL] [Abstract][Full Text] [Related]
3. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
Plouvier B; Beatch GN; Jung GL; Zolotoy A; Sheng T; Clohs L; Barrett TD; Fedida D; Wang WQ; Zhu JJ; Liu Y; Abraham S; Lynn L; Dong Y; Wall RA; Walker MJ
J Med Chem; 2007 Jun; 50(12):2818-41. PubMed ID: 17506538
[TBL] [Abstract][Full Text] [Related]
5. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
[TBL] [Abstract][Full Text] [Related]
6. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation.
McBride BF
J Clin Pharmacol; 2009 Mar; 49(3):258-67. PubMed ID: 19246727
[TBL] [Abstract][Full Text] [Related]
8. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
Guo X; Ma X; Yang Q; Xu J; Huang L; Jia J; Shan J; Liu L; Chen W; Chu H; Wei J; Zhang X; Sun H; Tang Y; You Q
Eur J Med Chem; 2014 Jun; 81():89-94. PubMed ID: 24824064
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
[TBL] [Abstract][Full Text] [Related]
13. [Synthesis and biological activity of 1-(4-alkyloxy)benzyl-1,2,3,4-tetrahydroisoquinolines and related compounds].
He L; Huang W; Gao H; Peng S
Yao Xue Xue Bao; 1998 Oct; 33(10):741-7. PubMed ID: 12016926
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.
Piatnitski Chekler EL; Butera JA; Di L; Swillo RE; Morgan GA; Rossman EI; Huselton C; Larsen BD; Hennan JK
Bioorg Med Chem Lett; 2009 Aug; 19(16):4551-4. PubMed ID: 19616941
[TBL] [Abstract][Full Text] [Related]
15. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
Guo X; Chen W; Sun H; You Q
Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
[TBL] [Abstract][Full Text] [Related]
16. [Synthesis and biological activity of substituted benzyl/naphthylmethylisoquinolines and related quaternary ammonium derivatives].
Xu GY; Peng SX; Hua WY
Yao Xue Xue Bao; 1994; 29(2):95-106. PubMed ID: 8042518
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
Peukert S; Brendel J; Pirard B; Strübing C; Kleemann HW; Böhme T; Hemmerle H
Bioorg Med Chem Lett; 2004 Jun; 14(11):2823-7. PubMed ID: 15125940
[TBL] [Abstract][Full Text] [Related]
18. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; Didomenico S; Koenig JR; Turner S; Jinkerson T; Drizin I; Hannick SM; Macri BS; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter J; Stewart KD; Oie T; Jarvis MF; Surowy CS; Faltynek CR; Lee CH
J Med Chem; 2005 Feb; 48(3):744-52. PubMed ID: 15689158
[TBL] [Abstract][Full Text] [Related]
19. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
Ford JW; Milnes JT
J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
[TBL] [Abstract][Full Text] [Related]
20. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
